Antischistosomal drugs: Past, present ... and future?

Pharmacology and Therapeutics

Volumn 68, Issue 1, 1995, Pages 35-85

  Cioli, Donato ^a   Pica Mattoccia, Livia ^a   Archer, Sydney ^b  

^a Institutes of Human Anatomy and Cell Biology   (Italy)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

anthelmintics; drug mechanisms; hycanthone; metrifonate; oxamniquine; praziquantel; Schistosomiasis

Indexed keywords

1,2,3,4 TETRAHYDRO 2 ISOPROPYLAMINOMETHYL 6 METHYL 7 NITROQUINOLINE; 2,3 DEHYDROEMETINE; 3 CHLORO N (2 DIETHYLAMINOETHYL) PARA TOLUIDINE; 5 AMINO 3 [2 (5 NITRO 2 FURYL)VINYL] 1,2,4 OXADIAZOLE; AMOSCANATE; ANTHELMINTIC AGENT; ANTIMONY TARTRATE; CYCLOSPORIN A; CYSTICIDE; DICHLORVOS; HYCANTHONE; IA 4; LUCANTHONE; MECLONAZEPAM; METRIFONATE; NIRIDAZOLE; OLTIPRAZ; OXAMNIQUINE; PRAZIQUANTEL; TUBERCIDIN; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS;

COMPARATIVE STUDY; FORECASTING; HUMAN; SCHISTOSOMIASIS; SCHISTOSOMICIDES; SUPPORT, NON-U.S. GOV'T;

EID: 0028895250     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(95)00026-7     Document Type: Review

References (323)

1. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood
2. Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects
3. History and scope of the conference
4. The Brazilian program for schistosomiasis control
5. ® in animals using a biological assay
6. A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action
7. Praziquantel: mechanisms of anti-schistosomal activity
8. 14C-praziquantel by cestodes, trematodes, and a nematode
9. Praziquantel
10. Oltipraz—definitely withdrawn
11. Chemoprotective effects of two dithiolethiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity
12. Praziquantel (antischistosomal drug): is it clastogenic, co-clastogenic or anticlastogenic?
13. Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantel
14. Enhancement of benzene clastogenicity by praziquantel in mice
15. The chemotherapy of schistosomiasis
16. Recent developments in the chemotherapy of schistosomiasis
17. Preparation and antischistosomal and antitumor activity of hycanthone and some of its congeners. Evidence for the mode of action of hycanthone
18. Mode of action of the schistosomicide hycanthone: site of DNA alkylation
19. Cyclophilin of Schistosoma japonicum
20. Preliminary results in human schistosomiasis with Ro 11-3128
21. Treatment of Schistosoma mansoni- and Schistosoma haematobium-infected mice with a combination of tubercidin and nucleoside transport inhibitor
22. The possible role of acetylcholine in Schistosoma mansoni
23. 1,2-Dithiolethiones
24. The immune response to a schistosomacide, amoscanate. I. Serum antibody responses
25. The immune response to a schistosomacide, amoscanate. II. Cellmediated immune responses
26. Praziquantel for treatment of schistosomiasis in patients with advanced splenomegaly
27. Mutagenic activities in vitro and in vivo of five antischistosomal compounds
28. Prevention of the mutagenic activation of an antischistosomal isothiocyanate in primates by an antibiotic
29. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro
30. Characteristics of antischistosomal benzodiazepine binding sites in Schistosoma mansoni
31. Oltipraz a laboratory and clinical review
32. Resistance following drug attenuation (Ro 11-3128 or oxamniquine) of early Schistosoma mansoni infections in mice
33. Le traitement des schistosomoses par les injections de 2-déhydro-émétine
34. Studies on the mode of action of metrifonate and DDVP in schistosomes. Cholinesterase activity and the hepatic shift
35. Relative importance of bacterial and mammalian nitroreductases for niridazole mutagenesis
36. Toxicogenetics of niridazole in inbred mice
37. Chemistry of schistosomicides
38. Protection against schistosomiasis produced by cyclosporin A
39. Antischistosomal effect of cyclosporin A: cure and prevention of mouse and rat schistosomiasis mansoni
40. Anti-schistosomal activity of cyclosporin A: studies on murine spleen cells and the influence of a cyclosporin antagonist on resistance to infection
41. The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds
42. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response
43. A genomic change associated with the development of resistance to hycanthone in Schistosoma mansoni
44. Role of host antibody in the chemotherapeutic action of praziquantel against Schistosoma mansoni: identification of target antigens
45. Characterization of a programmed alteration in an 18S ribosomal gene that accompanies the experimental induction of drug resistance in Schistosoma mansoni
46. New anthelmintics
47. Carbohydrate metabolism of Schistosoma mansoni
48. Acetylcholinesterase activity of Schistosoma mansoni
49. Hycanthone and other antischistosomal drugs: lack of obligatory association between chemotherapeutic effects and mutagenic activity
50. Factors affecting the inhibition of phosphofructokinase activity of Schistosoma mansoni by trivalent organic antimonials
51. The relationship between inhibition of phosphofructokinase activity and the mode of action of trivalent organic antimonials on Schistosoma mansoni
52. The antischistosomal activity of a nitrovinylfuran derivative (SQ 18,506) in mice and hamsters
53. Inhibition by metrifonate and dichlorvos of cholinesterases in schistosomes
54. The antischistosomal activity of a chloroindazole analog of hycanthone in mice infected with Schistosoma mansoni
55. Antischistosomal and some toxicological properties of a nitrodiphenylaminoisothiocyanate (C 9333-Go/CGP 4540)
56. Antischistosomal effects of cyclosporin A
57. The antischistosomal activity of oltipraz
58. Carcinogenic potential of hycanthone in mice and hamsters
59. The amount of acetylcholinesterase on the parasite surface reflects the differential sensitivity of schistosome species to metrifonate
60. Hycanthone resistance in a human strain of Schistosoma mansoni
61. 1-Thiocarbamyl-2-imidazolidinone, a metabolite of niridazole in Schistosoma mansoni
62. A new approach to helminthiasis control: the use of an organophosphorous compound
63. Studies on the action of cyclosporine A against Schistosoma mansoni and other parasitic infections
64. Dosage timing and route and administration of cyclosporin A and non immunosuppressive derivatives of dihydrocyclosporin A and cyclosporin C against Schistosoma mansoni in vivo and in vitro
65. Short-term effects of oxamniquine on the activity in vitro of Schistosoma mansoni
66. Activity of Schistosoma mansoni over a ten-hour period in vitro, and its modification by oxamniquine
67. The successful use of antimony in bilharziosis. Administered as intravenous injections of antimonium tartaratum (tartar emetic)
68. The toxicology of the schistosomicidal agent oxamniquine
69. Transfer of Schistosoma mansoni into the mesenteric veins of hamsters
70. A study of the mode of action of hycanthone against Schistosoma mansoni in vivo and in vitro
71. Genetic analysis of hycanthone resistance in Schistosoma mansoni
72. Evidence for the mode of antischistosomal action of hycanthone
73. Schistosoma mansoni: hycanthone/oxamniquine resistance is controlled by a single autosomal recessive gene
74. Drug resistance in schistosomes
75. Coordinate induction of glutathione S- transferase α, μ, and π expression in murine liver after a single administration of oltipraz
76. Schistosoma mansoni: preclinical studies with 9-acridanone-hydrazones in Cebus monkeys experimentally infected
77. Tolerance of Kenyan Schistosoma mansoni to oxamniquine
78. Absence of liver toxicity in 2723 patients treated with hycanthone in St. Lucia
79. Le traitement des bilharzioses
80. Differences in antischistosomal and mutagenic properties between an isothiocyano- and an isocyano-nitrodiphenylamine
81. Treatment of hepatosplenic schistosomiasis mansoni with niridazole: relationships among liver function, effective dose, and side effects
82. CIBA 32,644-Ba and spermatogenesis in man. Preliminary results
83. Management of the patient with schistosomiasis
84. Recent advances in schistosomiasis
85. Antischistosomal drugs and clinical practice
86. Metrifonate in urinary schistosomiasis
87. Multicentre trials of praziquantel in human schistosomiasis: design and techniques
88. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium
89. Praziquantel: the enigmatic antiparasitic
90. 7-alkylation in mice in vivo by metrifonate. Discussion of possible genotoxic risk in mammals
91. The effect of metrifonate in vitro on Schistosoma hematobium and Schistosoma mansoni adults
92. Tegumental disruption with Triton X-100 and its effects on longitudinal muscle function in male Schistosoma mansoni
93. Hycanthone: an unresolved case study in risk assessment
94. Stability of Schistosoma mansoni progeny to antischistosomal drugs
95. Failure at inducing resistance to schistosomicidal drugs in a Brazilian human strain of Schistosoma mansoni
96. Linhagem humana de Schistosoma mansoni resistente a esquistossomicidas
97. Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents
98. Quantitative determination of praziquantel in body fluids by gas liquid chromatography
99. The fate of praziquantel in the organism. III. Metabolism in rat, beagle dog and rhesus monkey
100. Cloning and characterization of a cDNA encoding phosphofructokinase from Schistosoma mansoni
101. The effect of metrifonate in mixed Schistosoma haematobium and Schistosoma mansoni infections in humans
102. Evidence for an immunedependent action of praziquantel on Schistosoma mansoni in mice
103. Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite esterase
104. Enzymatic differences between hycanthoneresistant and sensitive strains of Schistosoma mansoni
105. Carcinogenicity of the antischistosomal nitrofuran trans-5-amino-3-[2-(5 nitro-2-fury])vinyll-1,2,4-oxadiazole
106. Regulation of phase 2 enzyme induction by oltipraz and other dithiolthiones
107. Studies on some derivatives of oxamniquine
108. Efficacy of combination therapy with tubercidin and nitrobenzylthioinosine 5′-monophosphate against chronic and advanced stages of schistosomiasis
109. Combination therapy of schistosomiasis by tubercidin and nitrobenzylthioinosine 5′-monophosphate
110. Combination therapy of Schistosoma japonicum by tubercidin and nitrobenzylthioinosine 5′-monophosphate
111. Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors
112. The apparent absorption kinetics of Ro 15-5458, a schistosomicidal drug
113. Schistosoma mansoni: biochemical characteristics of the antischistosomal effects of Ro 15-5458
114. The schistosomicidal compound Ro 15-5458 causes a reduction in the RNA content of Schistosoma mansoni
115. The metabolism of niridazole (Ambilhar) in man. II. Investigations of patients suffering from clinically advanced forms of Schistosoma mansoni infection
116. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific
117. Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni
118. The toxicity of niridazole in rat embryos in vitro
119. Studies of mechanisms of niridazole-elicited embryotoxicity: evidence against a major role for covalent binding
120. The diagnosis and treatment of acute toxaemic schistosomiasis in children
121. Efficacy of metrifonate in urinary schistosomiasis: comparison of reduction of Schistosoma haematobium and S. mansoni eggs
122. Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of Schistosoma mansoni
123. Toward an understanding of the schistosomicidal effect of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (oltipraz)
124. Risks vs. benefits in antischistosomal therapy
125. Treatment of urinary schistosomiasis: practice and theory
126. Treatment of urinary schistosomiasis with trichlorfone
127. A review of clinical experience with oxamniquine
128. Studies with the schistosomicide oxamniquine (UK-4271). I: activity in rodents and in vitro
129. The control of immature Schistosoma mansoni in mice by UK 3883, a novel 2-aminomethyltetrahydroquinoline derivative
130. Studies with the schistosomicide oxamniquine (UK-4271). II: activity in primates
131. Laboratory trials on oxamniquine (UK-4271), a candidate schistosomicide
132. Results of toxicological studies on praziquantel
133. Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides
134. The effect of inhibitors on the hydrolysis of acetylcholine by four species of Schistosoma
135. Comparison of the characteristics of acetylcholinesterase present in four species of Schistosoma
136. Assessment of 35972 (Oltipraz) a new antischistosomal drug against Schistosoma haematobium, Schistosoma mansoni, and Schistosoma intercalatum
137. Extracorporeal haemofiltration in urinary schistosomiasis. Unsuccessful clinical trial in three cases of S. haematobium infection
138. Surgical recovery of schistosomes from the portal blood. Treatment of the parasitization in man
139. Praziquantel a new broad-spectrum antischistosomal agent
140. Praziquantel
141. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal
142. Resistência ao hycanthone e oxamniquine em doentes com esquistossomose forma clínica hepatintestinal
143. Long-term hepatocellular effects of hycanthone and of two other antischistosomal drugs in mice infected with Schistosoma mansoni
144. Hycanthone-induced hepatic changes in mice infected with Schistosoma mansoni
145. Metabolism studies of the antischistosomal drug praziquantel using tandem mass spectrometry: distribution of parent drug and ten metabolites obtained from control and schistosome-infected mouse urine
146. Praziquantel impairs the ability of exogenous serotonin to stimulate carbohydrate metabolism in intact Schistosoma mansoni
147. Chlorpromazine, other amphiphilic cationic drugs and praziquantel: effects on carbohydrate metabolism of Schistosoma mansoni
148. 2+ on the bilayer-isotropichexagonal transition of model membranes
149. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro
150. Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy
151. Early years of the Salmonella mutagen tester strains: lessons from hycanthone
152. Genetic activity spectra of some antischistosomal compounds, with particular emphasis on thioxanthenones and benzothiopyranoindazoles
153. Hycanthone: a frameshift mutagen
154. Metabolism of the schistosomicidal agent hycanthone by rats and rhesus monkeys
155. Evaluation of the carcinogenic and genotoxic potential of praziquantel in the Syrian hamster embryo cell transformation assay
156. Acetylcholine receptors in Schistosoma mansoni: visualization and blockade by hycanthone
157. Anticholinergic properties of the antischistosomal drug hycanthone
158. The mode of action of hycanthone revisited
159. Chemistry of metrifonate and dichlorvos
160. Oltipraz: administration with food increases its antischistosomal activity
161. Clinical studies on 4022 cases of schistosomiasis japonica treated with nithiocyaminum
162. Hycanthone analogs: dissociation of mutagenic effects from antischistosomal effects
163. Selective antagonists of benzodiazepines
164. Morphological alterations of Schistosoma japonicum associated with the administration of amoscanate
165. Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections
166. Antischistosomal action of tubercidin administered after absorption into red cells
167. Treatment of Schistosoma haematobium in the baboon with metrifonate
168. A comparison of the susceptibility to metrifonate of Schistosoma haematobium, S. mattheei and S. mansoni in hamsters
169. Experimentally produced resistance of Schistosoma mansoni to hycanthone
170. The effect of hycanthone on the distribution of Schistosoma mansoni in the mouse
171. Field trial of metrifonate in the treatment and prevention of schistosomiasis infection in man
172. Longitudinal evaluation of efficacy on control of schistosomiasis japonica with environmental modification and molluschiciding as chief approaches in Jijiaba Village, Anhui Province
173. Chemotherapy of schistosomiasis mansoni
174. Experimental chemotherapy of schistosomiasis mansoni
175. Estudo de uma cepa humana de Schistosoma mansoni resistente a agentes esquistossomicidas
176. Preliminary trials with praziquantel in human infections due to Schistosoma mansoni
177. Assessment of Oltipraz in schistosomiasis mansoni clinical trials
178. The metabolism of oxamniquine—a new schistosomicide
179. Schistosomiasis: extracorporeal filtration in the treatment of experimentally infected baboons
180. Schistosoma japonicum: treatment by extracorporeal haemofiltration
181. Chemopreventive drug development: perspectives and progress
182. Effectiveness of a single dose of hycanthone orally in experimental schistosomiasis in hamsters
183. Experimental studies on the therapy of schistosomiasis
184. Oxamniquine pharmacokinetics in healthy Kenyan African volunteers
185. Cost and effectiveness of different approaches to schistosomiasis control in Africa
186. Lung-shift effect of metrifonate (trichlorfone) in mice infected with Schistosoma mansoni in relation to the duration of infection
187. Review of the genotoxicity and carcinogenicity of antischistosomal drugs; is there a case for a study of mutation epidemiology? Report of a task group on mutagenic antischistosomals
188. Chemotherapy of experimental Schistosoma mansoni infection with a nitro-thiazole derivative CIBA 32,644-Ba
189. Eine neue gegen Bilharziose und Amoebiase wirksame Verbindung
190. Action de l'hycanthone aux diverses stades évolutifs de l'infection expérimentale de la souris par Schistosoma mansoni
191. Note préliminaire sur la toxicité pour l'homme d'un insecticide organophosphoré (Dipterex)
192. Aspects of the effect of thioxanthone on Schistosoma mansoni in mice and in vitro
193. Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice
194. The relative chemotherapeutic efficacy of a nitrovinylfuran (SQ 18,506) against immature and mature stages of Schistosoma mansoni
195. Laboratory studies of 35 972 RP, a new schistosomicidal compound
196. Isolation and partial characterization of the tegumental outer membrane of schistosomula of Schistosoma mansoni
197. Schistosoma mansoni: praziquantel-induced tegumental lesion exposes actin of surface spines and allows binding of actin depolymerizing factor, gelsolin
198. Phenithionate in schistosomiasis japonica
199. Comparative efficacy of praziquantel and its optic isomers in experimental therapy of schistosomiasis japonica in rabbits
200. The new insecticide 0,0-dimethyl-2,2,2-trichloro-1-hydroxyethyl-phosphonate
201. Identification and purification of immunosuppressive activity in urine of rats and a human patient treated with niridazole
202. Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma
203. Niridazole. II: a potent long-acting suppressant of cellular hypersensitivity
204. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis
205. Experimental chemotherapy
206. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni
207. Glutathione redox state, lipid peroxide levels, and activities of glutathione enzymes on oltipraz-treated adult Schistosoma mansoni
208. Effect of oltipraz on the susceptibility of adult Schistosoma mansoni to killing by mouse peritoneal exudate cells
209. Praziquantel in acute schistosomiasis
210. Mutation at the HPRT locus in patients with neurocysticercosis treated with praziquantel
211. Teratogenicity of hycanthone in mice
212. Metabolism of oltipraz and glutathione reductase inhibition
213. Transdermal patch delivery of acetylcholinesterase inhibitors
214. The larvicidal activity of cyclosporin A against Schistosoma mansoni in mice
215. Differential effects of oltipraz and its oxy-analogue on the viability of Schistosoma mansoni and the activity of glutathione S-transferase
216. Mechanisms of inactivation of Schistosoma mansoni and mammalian glutathione S-transferase activity by the antischistosomal drug oltipraz
217. The effect of hycanthone on nucleic acid synthesis by Schistosoma mansoni
218. Properties and drug sensitivity of adenosine triphosphatases from Schistosoma mansoni
219. Chemical carcinogens a review and analysis of the literature of selected chemicals and the establishment of the Gene-Tox carcinogen data base
220. The effect of cyclosporin A on the course of murine infection by Schistosoma mansoni
221. Transformation and action of metrifonate
222. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with Bilarcil
223. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil
224. Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam
225. Covalent binding of niridazole (Ambilhar) to tissue proteins in the rat
226. Preferential inhibition of acetylcholinesterase molecular forms in rat brain
227. Genetic activities of hycanthone and some other antischistosomal drugs
228. Mutagenic evaluation of antischistosomal drugs and their derivatives in Neurospora crassa
229. Genetic analysis of adenine-3 mutants induced by hycanthone, lucanthone and their indazole analogs in Neurospora crassa
230. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum
231. Action of praziquantel and the benzodiazepines on adult male Schistosoma mansoni
232. Niridazole, potent long-acting suppressant of cellular hypersensitivity. III: minimal suppression of antibody responses
233. Effect of hycanthone administered in vivo upon the incorporation of radioactive precursors into macromolecules of Schistosoma mansoni
234. Studies on the mode of action of oxamniquine and related schistosomicidal drugs
235. Lack of correlation between schistosomicidal and anticholinergic properties of hycanthone and related drugs
236. Effect of hycanthone on Schistosoma mansoni macromolecular synthesis in vitro
237. Sex and drugs in Schistosoma mansoni
238. Binding of tritiated hycanthone and hycanthone N-methylcarbamate to macromolecules of drug-sensitive and drug-resistant schistosomes
239. Binding of oxamniquine to the DNA of schistosomes
240. Hycanthone resistance in schistosomes correlates with the lack of an enzymatic activity which produces the covalent binding of hycanthone to parasite macromolecules
241. Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene
242. Effect of metrifonate on blood cholinesterases in children during the treatment of schistosomiasis
243. Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire
244. Action du CIBA 32,644-Ba sur la spermatogénèse. Etude préliminaire
245. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication
246. A fluorometric method for the determination of praziquantel in blood plasma and urine
247. A comparative study of the genetic effects of hycanthone and oxamniquine
248. Esterases in schistosomes: reaction with substrates and inhibitors
249. Mechanism of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of 0,0-dimethyl-2,2,2-trichlor-1-hydroxyethyl phosphonate (Trichlorfon)
250. Oxamniquine—a drug for the Third World
251. A new series of 2-aminomethyltetrahydroquinoline derivatives displaying schistosomicidal activity in rodents and primates
252. Relationship between structure, conformation, and antischistosomal activity of nitroheterocyclic compounds
253. Hycanthone resistance: development in Schistosoma mansoni
254. A new, active metabolite of ‘Miracil D.’
255. A possible metabolic basis for the schistosomicidal activity of mirasan and N-(3-chloro-4-methylphenyl)-piperazine
256. Results of tests for possible transmitted genetic effects of hycanthone in mammals
257. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice
258. Schistosoma mansoni: chemotherapy of infections of different ages
259. Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines
260. Identification and characterization of glycophosphatidylinositol-linked Schistosoma mansoni adult worm immunogens
261. Selective release of a glycophosphatidylinositol-anchored antigen from the surface of Schistosoma mansoni
262. Calcium dependence of toxic cell death: a final common pathway
263. Mode of insertion of praziquantel and derivatives into lipid membranes
264. The mechanism of action of cyclosporin A and FK506
265. Involvement of the central nervous system in Schistosoma mansoni and Schistosoma haematobium infection
266. Effect of hycanthone, niridazole, and antimony tartrate on schistosome motility
267. Hycanthone effects on schistosomes and its likely mode of action
268. Influence of hycanthone on the morphology and serotonin uptake of Schistosoma mansoni
269. Synthesis and properties of praziquantel, a novel broad spectrum anthelminthic with excellent activity against schistosomes and cestodes
270. Clinical evaluation of amoscanate in healthy male volunteers
271. Schistosoma mansoni: stage-dependent damage after in vivo treatment with praziquantel
272. Schistosoma mansoni: the effects of a subcurative dose of praziquantel on the ultrastructure of worms in vivo
273. Schistosoma mansoni: structural damage and tegumental repair after in vivo treatment with praziquantel
274. Schistosoma mansoni: praziquantel-induced changes to the female reproductive system
275. Evaluation of the teratogenic activity of hycanthone in mice and rabbits
276. Therapeutic properties of metrifonate
277. Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro
278. The fate of praziquantel in the organism. I. Pharmacokinetics in animals
279. Low efficacy and tolerance of praziquantel in a new, intense focus of Schistosoma mansoni infection
280. Ro 11-3128, a novel schistosomicidal compound
281. 4-Isothiocyanato-4′-nitrodiphenylamine (C 9333-Go/CGP 4540), an anthelminthic with an unusual spectrum of activity against intestinal nematodes, filariae and schistosomes
282. A note on the efficacy of a new class of compounds, 9-acridanone-hydrazones, against Schistosoma mansoni in a primate—the baboon
283. Parasitological evaluation of curative and subcurative doses of 9-acridanone-hydrazone drugs against Schistosoma mansoni in baboons, and observations on the changes in serum levels of anti-egg antibodies detected by ELISA
284. Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops)
285. Schistosoma: a 200 kDa chemotherapeutic target antigen is differently localized in African vs
286. Cyclosporin A: immune suppressant and antiparasitic agent
287. Effects of hycanthone on neuromuscular systems of Schistosoma mansoni
288. The formation of 1-thiocarbamyl-2-imidazolidinone from niridazole in mouse intestine
289. Isolation, characterization and synthesis of an immunoregulatory metabolite of niridazole: 1-thiocarbamyl-2-imidazolidinone
290. Reductive metabolism of niridazole by adult Schistosoma mansoni. Correlation with covalent drug binding to parasite macromolecules
291. Induction of hepatic neoplastic lesions in mice with a single dose of hycanthone methanesulfonate after partial hepatectomy
292. Carcinogenic effects of niridazole
293. Genomic variability in field populations of Schistosoma mansoni in Brazil as detected with a ribosomal gene probe
294. Schistosoma mansoni: tegumental surface alterations induced by subcurative doses of the schistosomicide amoscanate
295. Über den Einfluss des Geschlectspartners auf Wachstum und Entwicklung bei Bilharzia mansoni und bei Keuzpaarungen zwischen verschiedenen Bilharzia-Arten
296. Interaction of amoscanate with the cyclic AMP-phosphodiesterases from Schistosoma mansoni, Onchocerca volvulus and bovine heart
297. Variation in the supercoils in closed circular DNA by binding of antibiotics and drugs: evidence for molecular models involving intercalation
298. A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[a]anthracene
299. Praziquantel in treatment of cerebral schistosomiasis
300. Bloody diarrhoea after praziquantel treatment
301. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) on carcinogenesis induced by benzo(a)pyrene, diethylnitrosamine, and uracil mustard
302. A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. matthei in hamsters
303. Suppression of delayed hypersensitivity in schistosome-infected patients by niridazole
304. The profile of the trematodicidal compound praziquantel
305. Chemotherapy of schistosomiasis
306. Stereoselektive Biotransformation des Praziquantels in vivo und in vitro
307. High-performance liquid Chromatographic determination of the stereoselective biotransformation of the chiral drug praziquantel
308. Cercariae to liver worms: development and migration in the mammalian host
309. 14C]oxamniquine by Schistosoma mansoni
310. WHO reports on schistosomicidal drugs
311. Oxamniquine
312. The use of essential drugs: model list of essential drugs (Seventh list). Fifth Report of the WHO Expert Committee
313. Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica
314. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni
315. Quantitative determination of praziquantel in serum by high performance liquid chromatography
316. Praziquantel-induced vesicle formation in the tegument of male Schistosoma mansoni is calcium dependent
317. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo
318. The uptake of tritiated hycanthone by male and female Schistosoma mansoni worms and distribution of the drug in plasma and whole blood of mice following a single intramuscular injection
319. Effects of hycanthone against two strains of Schistosoma japonicum in mice
320. An 18-month study of the parasitologic and tumorigenic effects of hycanthone in Schistosoma mansoni-infected and noninfected mice
321. Failure to induce resistance of Schistosoma japonicum to praziquantel